144 related articles for article (PubMed ID: 31361813)
21. The use of anti-factor Xa monitoring in a selection of patients receiving enoxaparin at a large academic medical center.
Sacha GL; Greenlee KM; Ketz JM
J Thromb Thrombolysis; 2016 Nov; 42(4):479-85. PubMed ID: 27256341
[TBL] [Abstract][Full Text] [Related]
22. Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.
Lee YR; Vega JA; Duong HN; Ballew A
Pharmacotherapy; 2015 Nov; 35(11):1007-15. PubMed ID: 26598093
[TBL] [Abstract][Full Text] [Related]
23. Impact of Weight on Anti-Xa Attainment in High-Risk Trauma Patients on Enoxaparin Chemoprophylaxis.
Farrar JE; Droege ME; Philpott CD; Mueller EW; Ernst NE; Makley AT; Deichstetter KM; Droege CA
J Surg Res; 2021 Aug; 264():425-434. PubMed ID: 33848842
[TBL] [Abstract][Full Text] [Related]
24. Adjusted value of thromboprophylaxis in hospitalized obese patients: A comparative study of two regimens of enoxaparin: The ITOHENOX study.
Miranda S; Le Cam-Duchez V; Benichou J; Donnadieu N; Barbay V; Le Besnerais M; Delmas FX; Cuvelier A; Lévesque H; Benhamou Y; Armengol G
Thromb Res; 2017 Jul; 155():1-5. PubMed ID: 28460259
[TBL] [Abstract][Full Text] [Related]
25. Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity.
Thompson-Moore NR; Wanat MA; Putney DR; Liebl PH; Chandler WL; Muntz JE
Clin Appl Thromb Hemost; 2015 Sep; 21(6):513-20. PubMed ID: 25601898
[TBL] [Abstract][Full Text] [Related]
26. Management of Anticoagulation Therapy in Patients With Thromboembolism in the Context of Renal Dysfunction: Challenging Cases and Practical Algorithms.
Bahabri A; Chan AKC; Belostosky V; Bhatt MD
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e1040-e1044. PubMed ID: 33369999
[TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetics of enoxaparin in early stage of paediatric liver transplantation.
Oualha M; Chardot C; Debray D; Lesage F; Harroche A; Renolleau S; Treluyer JM; Urien S
Br J Clin Pharmacol; 2018 Jun; 84(6):1206-1214. PubMed ID: 29423936
[TBL] [Abstract][Full Text] [Related]
28. An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review.
Ho SH; Wu JK; Hamilton DP; Dix DB; Wadsworth LD
J Pediatr Hematol Oncol; 2004 Sep; 26(9):561-6. PubMed ID: 15342982
[TBL] [Abstract][Full Text] [Related]
29. Should we be following anti-factor Xa levels in patients receiving prophylactic enoxaparin perioperatively?
Pannucci CJ; Rondina MT
Surgery; 2017 Feb; 161(2):329-331. PubMed ID: 27712881
[No Abstract] [Full Text] [Related]
30. Weight-based enoxaparin with anti-factor Xa assay-based dose adjustment for venous thromboembolic event prophylaxis in adult trauma patients results in improved prophylactic range targeting.
Rodier SG; Bukur M; Moore S; Frangos SG; Tandon M; DiMaggio CJ; Ayoung-Chee P; Marshall GT
Eur J Trauma Emerg Surg; 2021 Feb; 47(1):145-151. PubMed ID: 31471669
[TBL] [Abstract][Full Text] [Related]
31. Association of outcomes and anti-Xa levels in the treatment of pediatric venous thromboembolism.
Fan JL; Roberts LE; Scheurer ME; Yee DL; Shah MD; Lee-Kim YJ
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28521068
[TBL] [Abstract][Full Text] [Related]
32. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
Ma JM; Jackevicius CA; Yeo E
Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
[TBL] [Abstract][Full Text] [Related]
33. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin.
Richard AA; Kim S; Moffett BS; Bomgaars L; Mahoney D; Yee DL
J Pediatr; 2013 Feb; 162(2):293-6. PubMed ID: 22959138
[TBL] [Abstract][Full Text] [Related]
34. If some is good, more is better: An enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis.
Berndtson AE; Costantini TW; Lane J; Box K; Coimbra R
J Trauma Acute Care Surg; 2016 Dec; 81(6):1095-1100. PubMed ID: 27244575
[TBL] [Abstract][Full Text] [Related]
35. An Evaluation of the Appropriateness of Initial Enoxaparin Dosing Among Pediatric Patients.
Altuwayjiri A; AlDarwish A; Alshuraim R
Cureus; 2023 Nov; 15(11):e48830. PubMed ID: 38106767
[TBL] [Abstract][Full Text] [Related]
36. Enoxaparin and antifactor Xa levels in pediatric acute burn patients.
Brown A; Faraklas I; Ghanem M; Cochran A
J Burn Care Res; 2013; 34(6):628-32. PubMed ID: 24043233
[TBL] [Abstract][Full Text] [Related]
37. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series.
Deal EN; Hollands JM; Riney JN; Skrupky LP; Smith JR; Reichley RM
J Thromb Thrombolysis; 2011 Aug; 32(2):188-94. PubMed ID: 21465129
[TBL] [Abstract][Full Text] [Related]
39. Assessing an enoxaparin dosing protocol in morbidly obese patients.
Lalama JT; Feeney ME; Vandiver JW; Beavers KD; Walter LN; McClintic JR
J Thromb Thrombolysis; 2015 May; 39(4):516-21. PubMed ID: 25087072
[TBL] [Abstract][Full Text] [Related]
40. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
